The SAVE-Care (SGLT2i As Novel Gout Care) consortium, represented by eight sites across four countries, was formed to investigate and generate evidence for the potential use of SGLT2i as part of a comprehensive gout and cardiometabolic comorbidity care plan. Through multicenter prospective observational studies and randomized controlled trials, we hope to eventually establish SGLTI2i as a viable treatment to prevent premature mortality in patients with gout.

What is SGLT2i?

SGLT2i is an acronym that stands for Sodium-Glucose Transport Protein 2 inhibitors. These medications inhibit sodium-glucose transport proteins in the kidney to prevent the kidney from absorbing glucose/sugar. Typically, we use SGLT2i to treat type 2 diabetes to control blood sugar levels, but past research, along with our own research, has shown that SGLT2i can also potentially help treat gout by lowering serum urate levels.

Where are we located?

Currently, our team is spread across eight centers:

• Massachusetts General Hospital (Boston, MA, USA)
• University of California San Diego (San Diego, CA, USA)
• University of Alabama at Birmingham (Birmingham, AL, USA)
• University of California Los Angeles (Los Angeles, CA, USA)
• University of Auckland (Auckland, New Zealand)
• University of Paris (Paris, France)
• Lille Catholic University (Lille, France)
• University of Nottingham (Nottingham, UK)